SONIA Trial and CDK4/6 Timing

The SONIA phase 3 trial asked a practical question.

Do CDK4/6 inhibitors need to be used in first line for everyone with HR-positive, HER2-negative advanced breast cancer.

The main answer was no.

In the overall study population, using a CDK4/6 inhibitor in first line did not improve overall survival compared with saving CDK4/6 treatment for second line.

First-line use also caused more grade 3 or higher toxic effects.

What SONIA tested

SONIA compared two sequencing strategies:

• first-line endocrine therapy plus a CDK4/6 inhibitor, then endocrine therapy alone in second line

• first-line endocrine therapy alone, then endocrine therapy plus a CDK4/6 inhibitor in second line

The goal was not to test whether CDK4/6 inhibitors work.

That is already well established.

The goal was to test whether earlier use improves the outcome that matters most long term.

Main finding

For the whole study population, overall survival was not better when the CDK4/6 inhibitor was used in first line.

That matters because CDK4/6 inhibitors are often presented as an immediate default.

SONIA suggests the timing can be more flexible than that.

Why this matters in practice

This does not mean CDK4/6 inhibitors are unhelpful.

It means some patients may be able to start with endocrine therapy alone and keep CDK4/6 inhibition for later without clearly losing overall survival.

That may be especially relevant when these issues matter a lot:

• side effects

• quality of life

• lab and ECG monitoring burden

• treatment cost

• personal preference around treatment intensity

The tradeoff

The price of earlier use in SONIA was more serious toxicity.

That matters because treatment burden is not abstract.

It affects daily life, dose reductions, interruptions, and how sustainable a regimen feels over time.

Important nuance

This should not be oversimplified.

A post hoc analysis suggested a possible overall-survival advantage for first-line CDK4/6 use in premenopausal patients.

That means the trial supports individualised sequencing, not a blanket rule to delay treatment.

Disease burden, pace of progression, menopausal status, prior endocrine exposure, and patient priorities still matter.

Bottom line

SONIA supports a more flexible discussion about CDK4/6 timing.

For the overall study population, first-line use did not improve overall survival over second-line use, and it caused more high-grade toxicity.

For some patients, that makes endocrine therapy first, CDK4/6 later a reasonable oncology discussion rather than an inferior fallback.

Key References

Overall survival with first-line versus second-line use of CDK4/6 inhibitors in hormone receptor-positive, ERBB2-negative advanced breast cancer: the SONIA randomized clinical trial
https://jamanetwork.com/journals/jamaoncology/fullarticle/2845273

PubMed entry for the SONIA overall survival analysis
https://pubmed.ncbi.nlm.nih.gov/41712229/

Earlier SONIA report on first-line versus second-line strategy and toxicity context
https://pubmed.ncbi.nlm.nih.gov/37382948/

News summary of the practical sequencing implications
https://www.cancertherapyadvisor.com/news/no-survival-benefit-first-line-cdk46i-advanced-breast-cancer/